Quantification of pulmonary fibrosis in a bleomycin mouse model using automated histological image analysis

PLoS ONE

Volumn 12, Issue 1, 2017, Pages

  Gilhodes, Jean Claude ^a   Julé, Yvon ^a   Kreuz, Sebastian ^b   Stierstorfer, Birgit ^b   Stiller, Detlef ^b   Wollin, Lutz ^b  

^a Biocellvia   (France)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASHCROFT SCORE; AUTOMATED SOFTWARE HISTOLOGICAL IMAGE ANALYSIS; BLEOMYCIN-INDUCED PULMONARY FIBROSIS; CONTROLLED STUDY; DIGITAL IMAGING; HISTOPATHOLOGY; IMAGE PROCESSING; IMAGE QUALITY; IMAGE RECONSTRUCTION; IMAGING SOFTWARE; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG PARENCHYMA; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; MOUSE MODEL; NONHUMAN; OBSERVER VARIATION; PULMONARY TISSUE DENSITY; QUANTITATIVE ANALYSIS; RELIABILITY; RESPIRATORY TRACT DISEASE ASSESSMENT; RESPIRATORY TRACT PARAMETERS; VALIDATION PROCESS; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DIAGNOSTIC IMAGING; DISEASE MODEL; DRUG EFFECTS; LABORATORY AUTOMATION; LUNG; PATHOLOGY; PROCEDURES; PULMONARY FIBROSIS; SEVERITY OF ILLNESS INDEX;

ANIMALS; AUTOMATION, LABORATORY; BLEOMYCIN; DISEASE MODELS, ANIMAL; LUNG; MALE; MICE; MICE, INBRED C57BL; PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; X-RAY MICROTOMOGRAPHY;

EID: 85010383562     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0170561     Document Type: Article

References (39)

1. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, et al. (2015) An Official ATS/ERS/JRS/ ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 192: 3-19.
2. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370: 2071-2082. doi: 10.1056/ NEJMoa1402584 PMID: 24836310
3. King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370: 2083-2092. doi: 10.1056/NEJMoa1402582 PMID: 24836312
4. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M (2008) The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 40: 362-382. doi: 10.1016/j.biocel.2007.08.011 PMID: 17936056
5. Schaefer CJ, Ruhrmund DW, Pan L, Seivert SD, Kossen K (2011) Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 20: 85-97. doi: 10.1183/09059180.00001111 PMID: 21632796
6. Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B (2014) Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 349: 209-220. doi: 10.1124/jpet.113.208223 PMID: 24556663
7. Borzone G, Moreno R, Urrea R, Meneses M, Oyarzun M, Lisboa C (2001) BLM-induced chronic lung damage does not resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 163: 1648-1653.
8. Scotton CJ, Chamber RC (2010) BLM revisited: towards a more representative model of IPF?. Am J Physiol Lung Cell Mol Physiol 299: L439-L441.
9. Manali ED, Moschos C, Triantafillidou C, Kotanidou A, Psallidas I, Karabela SP, et al. (2011) Static and dynamic mechanics of the murine lung after intratracheal bleomycin. BMC Pulmonary Medicine 11: 33-47. doi: 10.1186/1471-2466-11-33 PMID: 21627835
10. Babin AL, Cannet C, Gérard C, Saint-Mezard P, Page CP, Sparrer H, et al. (2012) Bleomycin-Induced Lung Injury in Mice Investigated by MRI: Model Assessment for Target Analysis. Magn Reson Med 67: 499-509. doi: 10.1002/mrm.23009 PMID: 21656559
11. De Langhe E, Vande Velde G, Hostens J, Himmelreich U, Emery B, Luyten FP, et al. (2012) Quantification of lung fibrosis and emphysema in mice using automated micro-computed tomography. Plos One 7: e43123. doi: 10.1371/journal.pone.0043123 PMID: 22912805
12. Egger C, Cannet C, Gérard C, Jarman E, Jarai G, Feige A, et al. (2013) Administration of bleomycin via the oropharyngeal aspiration route leads to sustained lung fibrosis in mice and rats as quantified by UTE-MRI and histology. Plos One 8: e63432. doi:10.1371/journal.pone.0063432 PMID: 23667616
13. Scotton CJ, Hayes B, Alexander R, Datta A, Forty EJ, Mercer PF, et al. (2013) Ex vivo micro-computed tomography analysis of BLM-induced lung fibrosis for preclinical drug evaluation. Eur Respir 42: 1633-1645
14. Egger C, Gérard C, Vidotto N, Accart N, Cannet C, Dunbar A, et al. (2014) Lung volume quantified by MRI reflects extracellular-matrix deposition and altered pulmonary function in bleomycin models of fibrosis: effects of SOM230. Am J Physiol Lung Cell Mol Physiol 306: L1024-L1077.
15. Gammon ST, Foje N, Brewer EM, Owers E, Downs CA, Budde MD, et al. (2014) Preclinical anatomical, molecular, and functional imaging of the lung with multiple modalities. Am J Physiol Lung Cell Mol Physiol 306: L897-L914. doi: 10.1152/ajplung.00007.2014 PMID: 24658139
16. Vande Velde G, De Langhe E, Poelmans J, Dresselaers T, Lories RJ, Himmelreich U (2014) Cross-validation and comparison of different magnetic resonance imaging protocols with micro-computed tomography and histology in the bleomycin-induced mouse model. Invest Radiol 49: 691-698. doi: 10.1097/ RLI.0000000000000071 PMID: 24872004
17. Fernandez IE, Amarie OV, Mutze K, Königshoff M, Yildirim AO, Eickelberg O (2016) Systematic phenotying and correlation of biomarkers with lung function and histology in lung fibrosis. Am J Physiol Lung Cell Mol Physiol 310: L919-L927. doi: 10.1152/ajplung.00183.2015 PMID: 26993522
18. Vande Velde G, Poelmans J, De Langhe E, Hillen A, Vanoirbeek J, Himmelreich U, et al. (2016) Longitudinal micro-CT provides biomarkers of lung disease that can be used to assess the effect of therapy in preclinical mouse models, and reveal compensatory changes in lung volume. Disease Models Mechanisms 9: 91-98. doi: 10.1242/dmm.020321 PMID: 26563390
19. Ashcroft T, Simpson JM, Timbrell V (1988) Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 41: 467-470. PMID: 3366935
20. Húbner R, Gitter W, El Mokhtari NE, Mathiak M, Both M, Bolte H, et al. (2008) Standardized quantification of pulmonary fibrosis in histological samples. BioTechniques 299: L439-L441.
21. Izumo T, Kondo M, Nagai A (2009) Effects of a leukotriene B4 receptor antagonist on bleomycininduced pulmonary fibrosis. Eur Respir J 34: 1444-1451. doi: 10.1183/09031936.00143708 PMID: 19460787
22. Phillips EJ, Peng R, Burns L, Harris P, Garrido R, Tyagi G, et al. (2012) BLM- induced lung fibrosis increases work of breathing in the mouse. Pul Pharmacol Ther 25: 281-285.
23. Weng T, Poth JS, Karmouty-Quintana H, Garcia-Morales LJ, Melicoff E, Luo F, et al. (2014) Hypoxiainduced deoxycytidine kinase contributes to epithelial proliferation in pulmonary fibrosis. Am J Respir Crit Care Med 190: 1402-1412. doi: 10.1164/rccm.201404-0744OC PMID: 25358054
24. Bei Y, Hua-Huy T, Nicco C, Duong-Quy S, Le-Dong NN, Tiev KP, et al. (2016) RhoA/Rho-kinase activation promotes lung fibrosis in an animal model of systemic sclerosis. Exp Lung Res 42: 44-55. doi: 10. 3109/01902148.2016.1141263 PMID: 26873329
25. Rydell-Törmanen K, Andréasson K, Hesselstrand R, Risteli J, Heinegard D, Saxne T, et al. (2012) Extracellular matrix alterations and acute inflammation; developing in parallel during early induction of pulmonary fibrosis. Lab Invest 92: 917-925. doi: 10.1038/labinvest.2012.57 PMID: 22469699
26. Cicko S, Grimm M, Ayata K, Beckert J, Meyer A, Hossfeld M, et al. (2015) Uridine supplementation exerts anti-inflammatory and anti-fibrotic effects in an animal model of pulmonary fibrosis. Respir Res 16: 105-115. doi: 10.1186/s12931-015-0264-9 PMID: 26369416
27. Chow LN, Schreiner P, Ng BY, Lo B, Hughes MR, Wilder Scott R, et al. (2016) Impact of a CXCL12/ CXCR4 antagonist in bleomycin (BLM) induced pulmonary fibrosis and carbon tetrachloride (CCL4) induced hepatic fibrosis in mice. Plos one 11: e0151765. doi: 10.1371/journal.pone.0151765 PMID: 26998906
28. Pickering JG, Boughner DR (1991) Quantitative assessment of the age of fibrotic lesions using polarized light microscopy and digital imaging analysis. Am J Pathol 138: 1225-1231. PMID: 2024708
29. Decologne N, Wettstein G, Kolb M, Margetts P, Garrido C, Camus P, et al. (2010) Bleomycin induces pleural and subpleural fibrosis in the presence of carbon particles. Eur Respir J 35: 176-185. doi: 10. 1183/09031936.00181808 PMID: 19574324
30. Jarman ER, Khambata VS, Cope C, Jones P, Roger J, Ye LY, et al. (2014) An inhibitor of NADPH oxydase- 4 attenuates established pulmonary fibrosis in a rodent disease model. Am J Physiol Lung Cell Mol biol 50: 158-169.
31. Stumm CL, Wettlaufer SH, Jancar S, Peters-Golden M, et al. (2011) Airway remodeling in murine asthma correlates with a defect in PGE2 synthesis by lung fibroblasts. Am J Physiol Lung Cell Mol Physiol 301: L636-L644. doi: 10.1152/ajplung.00158.2011 PMID: 21873451
32. Ask K, Labiris R, Farkas L, Moeller A, Froese A, Farncombe T, et al. (2008) Comparison between conventional and clinical assessment of experimental lung fibrosis. J Translational Medicine 6: 1-10.
33. Artaechevarria X, Blanco D, Perez-Martin D, de Biurrun G, Montuenga LM, de Torres JP, et al. (2010) Longitudinal study of a mouse model of chronic pulmonary inflammation using breath hold gated micro- CT. Eur Radiol 20: 2600-2608. doi: 10.1007/s00330-010-1853-0 PMID: 20574632
34. Vasilescu DM, Knudsen L, Ochs M, Weibel ER, Hoffman EA (2012) Optimized murine lung preparation for detailed structural evaluation via micro-computed tomography. J Appl Physiol 112: 159-166. doi: 10.1152/japplphysiol.00550.2011 PMID: 21817110
35. Rodt T, von Falk C, Dettmer S, Halter R, Maus R, Ask K, et al. (2010) Micro-computed tomography of pulmonary fibrosis in mice induced by adenoviral gene transfert of biologically active transforming growth factor-β1. Respir Res 11: 181-188. doi: 10.1186/1465-9921-11-181 PMID: 21176193
36. Cavanaugh D, Travis EL, Price RE, Gladish G, White RA, Wang M, et al. (2006) Quantification of BLMinduced lung damage in vivo with micro-computed tomography. Acamedic Radiology 13: 1505-1512.
37. Ford NL, Martin EL, Lewis JF, Veldhuizen RA, Holdsworth DW, DrangovaM (2009) Quantifying lung morphology with respiratory-gated micro-CT in a murine model of emphysema. Phys Med Biol 54: 2121-2130. doi: 10.1088/0031-9155/54/7/018 PMID: 19287083
38. Thiesse J, Namati E, Sieren JC, Smith AR, Reinhardt JM, Hoffman EA, et al. (2010) Lung structure phenotype variation in inbred mouse strains revealed through in vivo micro-CT imaging. J Appl Physiol 109: 1960-1968. doi: 10.1152/japplphysiol.01322.2009 PMID: 20671036
39. Hsia CCW, Hyde DM, Ochs M, Weibel ER (2010) An official research policy statement of the american thoracic society/american respiratory society: standards for quantitative assessment of lung structure. Am J Respir Crit Care Med 181: 394-418. doi: 10.1164/rccm.200809-1522ST PMID: 20130146